NEW YORK, June 9, 2017 /PRNewswire/ --
On Thursday, June 08, 2017, US markets saw amixed session as 4 sectors closed in green, 3 sectors finished in red, and 2 sectors ended flat for the day. Major US indices were bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,321.76, up 0.39%; the Dow Jones Industrial
Waltham, Massachusetts headquartered PAREXEL International Corp.'s stock finished Thursday's session 1.23% higher at $82.61 with a total trading volume of 508,349 shares. The Company's shares have advanced 10.87% in the past month, 27.41% over the previous three months, and 25.70% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.96% and 24.36%, respectively. Furthermore, shares of PAREXEL, which provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have a Relative Strength Index (RSI) of 82.66.
On May 30th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $66 a share to $75 a share. Visit us today and download your complete report on PRXL for free at:
Shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. ended at $171.34, down 0.35% from the last trading session. The stock recorded a trading volume of 475,012 shares. The Company's shares have gained 5.73% in the last one month, 14.68% in the previous three months, and 46.11% on an YTD basis. The stock is trading 6.22% above its 50-day moving average and 29.70% above its 200-day moving average. Moreover, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 74.40. The complimentary research report on IDXX can be accessed at:
Dublin, Ireland headquartered ICON PLC's stock ended yesterday's session 0.91% higher at $97.69 with a total trading volume of 398,242 shares. The Company's shares have advanced 11.21% in the past month, 21.57% over the previous three months, and 29.91% on an YTD basis. The stock is trading 14.72% and 21.22% above its 50-day and 200-day moving averages, respectively. Additionally, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the US, and internationally, have an RSI of 79.07. Register for free on DailyStockTracker.com and download the research report on ICLR at:
PRA Health Sciences
On Thursday, shares in PRA Health Sciences Inc. recorded a trading volume of 450,650 shares. The stock finished 1.85% higher at $74.77. The Company's shares have advanced 11.78% in the last one month, 27.31% in the previous three months, and 35.65% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.04% and 27.32%, respectively. Furthermore, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 76.85. Get free access to your research report on PRAH at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All